Movement disorders in autoimmune diseases

Movement Disorders

Volumn 27, Issue 8, 2012, Pages 935-946

  Baizabal Carvallo, José Fidel ^a   Jankovic, Joseph ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Antiphospholipid syndrome; Autoimmune; Celiac disease; Chorea, ataxia; Movement disorders; Paraneoplastic; Systemic lupus erythematosus

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTICOAGULANT AGENT; AZATHIOPRINE; BACLOFEN; BOTULINUM TOXIN A; CARBAMAZEPINE; CLONIDINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; IMMUNOGLOBULIN; LEVODOPA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PENICILLIN G; PIMOZIDE; RISPERIDONE; RITUXIMAB; TACROLIMUS; TETRABENAZINE; VALPROIC ACID;

ANTIPHOSPHOLIPID SYNDROME; ATAXIA; AUTOIMMUNE DISEASE; BLOOD BRAIN BARRIER; CELIAC DISEASE; CHOREA MINOR; CLINICAL FEATURE; COGNITIVE DEFECT; DYSARTHRIA; DYSTONIA; ENCEPHALITIS; GILLES DE LA TOURETTE SYNDROME; HEMIBALLISM; HEMIPARESIS; HUMAN; MOTOR DYSFUNCTION; MUSCLE HYPOTONIA; MYOCLONUS; OBSESSIVE COMPULSIVE DISORDER; PAPILLEDEMA; PARANEOPLASTIC CHOREA; PARANEOPLASTIC SYNDROME; PARKINSONISM; PEDIATRIC AUTOIMMUNE NEUROPSYCHIATRIC DISORDERS ASSOCIATED WITH STREPTOCOCCAL INFECTION; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; RHEUMATIC FEVER; SEIZURE; SENSORY NEUROPATHY; SJOEGREN SYNDROME; STIFF MAN SYNDROME; STREPTOCOCCUS INFECTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TIC; UNSPECIFIED SIDE EFFECT;

EID: 85027922789     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25011     Document Type: Review

References (213)

1. Alarcon F, Gimenez-Roldan S. Systemic diseases that cause movement disorders. Parkinsonism Relat Disord 2005; 11: 1-18.
2. Mehta SH, Morgan JC, Sethi KD. Paraneoplastic movement disorders. Curr Neurol Neurosci Rep 2009; 9: 285-291.
3. Grant R, Graus F. Paraneoplastic movement disorders. Mov Disord 2009; 24: 1715-1724.
4. Tranchant C, Bhatia KP, Marsden CD. Movement disorders in multiple sclerosis. Mov Disord 1995; 10: 418-423.
5. Sydenham T. The Entire Works of Thomas Sydenham. Vols 1 and 2. London, England: Sydenham Society; 1848. Reprinted by: Birmingham, AL: Classics in Medicine Society; 1979.
6. Jummani R, Okun M. Sydenham's chorea. Arch Neurol 2001; 58: 311-313.
7. Kirvan CA, Swedo SE, Heuser JS, Cunningham MW. Mimicry and autoantibody mediated neural cell signaling in Sydenham chorea. Nat Med 2003; 9: 914-920.
8. Hallet M, Kaufman C. Physiological observations in Sydenham's chorea. J Neurol Neurosurg Psychiatry 1981; 44: 829-832.
9. Cardoso F. Huntington disease and other choreas. Neurol Clin 2009; 27: 719-736.
10. Cardoso F, Silva CE, Mota CC. Sydenham's chorea in 50 consecutive patients with rheumatic fever. Mov Disord 1997; 12: 701-703.
11. de Texeira AL, Cardoso F, Maia DP, et al. Frequency and significance of vocalization in Sydenham's chorea. Parkinsonism Relat Disord 2009; 15: 165-167.
12. Maia DP, Teixeira ALJr, Quintao Cunningham MC, Cardoso F. Obsessive compulsive behavior, hyperactivity, and attention deficit disorder in Sydenham's chorea. Neurology 2005; 64: 1799-1801.
13. Cardoso F, Beato R, Siqueira CF, et al. Neuropsychological performance and brain SPECT imaging in adult patients with Sydenham's chorea. Neurology 2005; 64( Suppl 1): 76.
14. Cunningham MC, Maia DP, Texeira ALJr, Cardoso F. Sydenham's chorea is associated with decreased verbal fluency. Parkinsonism Relat Disord 2006; 12: 165-167.
15. Kirvan CA, Swedo SE, Kurahara D, Cunningham MW. Streptococcal mimicry and antibody-mediated cell signaling in the pathogenesis of Sydenham's chorea. Autoimmunity 2006; 39: 21-29.
16. Bronze MS, Dale JB. Epitopes of streptococcal M proteins that evoke antibodies that cross-react with human brain. J Immunol 1993; 151: 2820-2828.
17. Church AJ, Cardoso F, Dale RC, Lees AJ, Thompson EJ, Giovannoni G. Anti-basal ganglia antibodies in acute and persistent Sydenham's chorea. Neurology 2002; 59: 227-231.
18. Church AJ, Dale RC, Giovannoni G. Anti-basal ganglia antibodies: a possible diagnostic utility in idiopathic movement disorders? Arch Dis Child 2004; 89: 611-614.
19. Singer HS, Hong JJ, Rippel CA, Pardo CA. The need for caution in considering the diagnostic utility of antibasal ganglia antibodies in movement disorders. Arch Dis Child 2004; 89: 595-597.
20. Kirvan CA, Cox CJ, Swedo SE, Cunningham MW. Tubulin is a neuronal target of autoantibodies in Sydenham's chorea. J Immunol 2007; 178: 7412-7421.
21. Teixeira ALJr, Cardoso F, Souza AL, Texeira MM. Increased serum concentrations of monokine induced by interferon-gamma/CXCL9 and interferon-gamma-inducible protein 10/CXCL-10 in Sydenham's chorea patients. J Neuroimmunol 2004; 150: 157-162.
22. Church AJ, Dale RC, Cardoso F, et al. CSF and serum immune parameters in Sydenham's chorea: evidence of an autoimmune syndrome? J Neuroimmunol 2003; 136: 149-153.
23. Bryant PA, Robins-Browne R, Carapetis JR, Curtis N. Some of the people, some of the time. Susceptibility to acute rheumatic fever. Circulation 2009; 119: 742-753.
24. Cardoso F. Sydenham's chorea. Curr Treat Options Neurol 2008; 10: 230-235.
25. Teixeira AL, Cardoso F, Maia DP, Cunningham MC. Sydenham's chorea may be a risk factor for drug induced parkinsonism. J Neurol Neurosurg Psychiatry 2003; 74: 1350-1351.
26. Jankovic J. Treatment of hyperkinetic movement disorders. Lancet Neurol 2009; 8: 844-856.
27. Garvey MA, Snider LA, Leitman SF, Werden R, Swedo SE. Treatment of Sydenham's chorea with intravenous immunoglobulin, plasma exchange, or prednisone. J Child Neurol 2005; 20: 424-429.
28. Enzler MJ, Berbari E, Osmon DR. Antimicrobial prophylaxis in adults. Mayo Clin Proc 2011; 86: 686-701.
29. Swedo SE, Leonard HL, Kiessling LS: Speculations on antineuronal antibody-mediated neuropsychiatric disorders of childhood. Pediatrics 1994; 93: 323-326.
30. Swedo SE, Leonard HL. Childhood movement disorders and obsessive compulsive disorder. J Clin Psychiatry 1994; 55: 32-37.
31. Swedo SE, Leonard HL, Mittleman BB, et al. Identification of children with pediatric autoinmune neuropsychiatric disorders associated with streptococcal infections by a marker associated with rheumatic fever. Am J Psychiatric 1997; 154: 110-112.
32. Swedo SE, Leckman JF, Rose NR. From Research Subgroup to Clinical Syndrome: Modifying the PANDAS Criteria to Describe PANS (Pediatric Acute-onset Neuropsychiatric Syndrome). Pediatr Therapeut 2012, 2: 2-8.
33. Kurlan R. The PANDAS hypothesis: losing its bite? Mov Disord 2004; 19: 371-374.
34. Jankovic J, Kurlan R. Tourette syndrome: Evolving concepts. Mov Disord 2011; 26: 1149-1156.
35. Morshed SA, Parveen S, Leckman JF, et al. Antibodies against neural nuclear, cytoskeletal, and streptococcal epitopes in children and adults with Tourette's syndrome, Sydenham's chorea, and autoimmune disorders. Biol Psychiatry 2001; 50: 566-577.
36. Cardona F, Orefici G. Group A streptococcal infections and tic disorders in an Italian pediatric population. J Pediatr 2001; 138: 71-75.
37. Muller N, Riedel M, Straube A, Gunther W, Wilske B. Increased antistreptococcal antibodies in patients with Tourette's syndrome. Psychiatry Res 2000; 94: 43-49.
38. Muller N, Kroll B, Schwarz MJ, et al. Increased titers of antibodies against streptococcal M12 and M19 proteins in patients with Tourette's syndrome. Psychiatry Res 2001; 101: 187-193.
39. Rizzo R, Gulisano M, Pavone P, Fogliani F, Robertson MM. Increased antistreptococcal antibody titers and anti-basal ganglia antibodies in patients with Tourette syndrome: controlled cross-sectional study. J Child Neurol 2006; 21: 747-753.
40. Church AJ, Dale RC, Lees AJ, Giovannoni G, Robertson MM. Tourette's syndrome: a cross sectional study to examine the PANDAS hypothesis. J Neurol Neurosurg Psychiatry 2003; 74: 602-607.
41. Martino D, Church AJ, Defazio G, et al. Soluble adhesion molecules in Gilles de la Tourette's syndrome. J Neurol Sci 2005; 234: 79-95.
42. Mell LK, Davis RL, Owens D. Association between streptococcal infection and obsessive-compulsive disorder, Tourette's syndrome, and tic disorder. Pediatrics 2005; 116: 56-60.
43. Leslie DL, Kozma L, Martin A, et al. Neuropsychiatric disorders associated with streptococcal infection: a case-control study among privately insured children. J Am Acad Child Adolesc Psychiatry 2008; 47: 1166-1172.
44. Schrag A, Gilbert R, Giovannoni G, Robertson MM, Metcalf C, Ben-Shlomo Y. Streptococcal infection, Tourette syndrome, and OCD: is there a connection? Neurology 2009; 73: 1256-1263.
45. Luo F, Leckman JF, Katsovich L, et al. Prospective longitudinal study of children with tic disorders and/or obsessive-compulsive disorder: relationship of symptom exacerbations to newly acquired streptococcal infections. Pediatrics 2004; 113: e578-e585.
46. Perrin EM, Murphy ML, Casey JR, et al. Does group A beta-hemolytic streptococcal infection increase risk for behavioral and neuropsychiatric symptoms in children? Arch Pediatr Adolesc Med 2004; 158: 848-856.
47. Kurlan R, Johnson D, Kaplan EL, and the Tourette Syndrome Study Group. Streptococcal infection and exacerbations of childhood tics and obsessive-compulsive symptoms: a prospective blinded cohort study. Pediatrics 2008; 121: 1188-1197.
48. Leckman JF, King RA, Gilbert DL, et al. Streptococcal upper respiratory tract infections and exacerbations of tic and obsessive-compulsive symptoms: a prospective longitudinal study. J Am Acad Child Adolesc Psychiatry. 2011; 50: 108-118.
49. Singer HS, Loiselle CR, Lee O, Minzer K, Swedo S, Grus FH. Anti-basal ganglia antibodies in PANDAS. Mov Disord 2004; 19: 406-415.
50. Giedd JN, Rapoport JL, Kruesi MJ, et al. Sydenham's chorea: Magnetic resonance imaging of the basal ganglia. Neurology 1995; 45: 2199-2202.
51. Giedd JN, Rapoport JL, Garvey MA, Pelmutter S, Swedo S. MRI assessment of children with obsessive compulsive disorder or tics associated with streptococcal infection. Am J Psychiatry 2000; 157: 281-283.
52. Singer HS, Gause C, Morris C, Lopez P, Tourette Syndrome Study Group. Serial immune markers do not correlate with clinical exacerbations in pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections. Pediatrics 2008; 121: 1198-1205.
53. Allen AJ, Leonard HL, Swedo SE. Case study: a new infection-triggered autoimmune subtype of pediatric OCD and Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 1995; 34: 307-311.
54. Brilot F, Merheb V, Ding A, Murphy T, Dale RC. Antibody binding to neuronal surface in Sydenham chorea, but not in PANDAS or Tourette syndrome. Neurology 2011; 76: 1508-1513.
55. Loiselle CR, Wendlandt JT, Rohde CA, Singer HS. Antistreptococcal, neuronal, and nuclear antibodies in Tourette syndrome. Pediatr Neurol 2003; 28: 119-125.
56. Morris CM, Pardo-Villamizar C, Gause CD, Singer HS. Serum autoantibodies measured by immunofluorescence confirm a failure to differentiate PANDAS and Tourette syndrome from controls. J Neurol Sci 2009; 276: 45-48.
57. Dale RC, Heyman I, Surtees RA, et al. Dyskinesias and associated psychiatric disorders following streptococcal infections. Arch Dis Child 2004; 89: 604-610.
58. Elia J, Dell ML, Friedman DF, et al. PANDAS with catatonia: a case report. Therapeutic response to lorazepam and plasmapheresis. J Am Acad Child Adolesc Psychiatry 2005; 44: 1145-1150.
59. Edwards MJ, Dale RC, Church AJ, Giovannoni G, Bathia KP. A dystonic syndrome associated with anti-basal ganglia antibodies. J Neurol Neurosurg Psychiatry 2004; 75: 914-916.
60. Garvey MA, Perlmutter SJ, Allen AJ, et al. A pilot study of penicillin prophylaxis for neuropsychiatric exacerbations triggered by streptococcal infections. Biol Psychiatry 1999; 45: 1564-1571.
61. Budman C, Coffey BJ, Dure L, et al. Regarding "antibiotic prophylaxis with azithromycin or penicillin for childhod-onset neuropsychiatric disorders". Biol Psychiatry 2005; 58: 917.
62. Snider LA, Lougee L, Slattery M, et al. Antibiotic prophylaxis with azithromycin or penicillin for childhood-onset neuropsychiatric disorders. Biol Psychiatry 2005; 57: 788-792.
63. Leonard HL. New developments in the treatments of obsessive-compulsive disorders. J Clin Psychiatry 1997; 58: 39-45.
64. Perlmutter SJ, Leitman SF, Garvey MA, et al. Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. Lancet 1999; 354: 1153-1158.
65. Singer HS. PANDAS and immunomodulatory therapy. Lancet 1999; 354: 1137-1138.
66. Tuzum E, Dalmau J. Limbic encephalitis and variants: classification, diagnosis and treatment. The Neurologist 2007; 13: 261-271.
67. Graus F, Dalmau J. Autoantibodies and neuronal autoimmune disorders of the CNS. J Neurol 2010; 257: 509-517.
68. Stich O, Jarius S, Kleer B, Rasiah C, Voltz R, Rauer S. Specific antibody index in cerebrospinal fluid from patients with central and peripheral paraneoplastic neurological syndromes. J Neuroimmunol 2007; 183: 220-224.
69. Graus F, Illa I, Augusti M, Ribalta T, Cruz-Sanchez F, Juarez C. Effect of intraventricular injection of an anti-Purkinje cell antibody (anti-Yo) in a guinea pig model. J Neurol Sci 1991; 106: 82-87.
70. Albert ML, Austin LM, Darnell RB. Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann Neurol 2000; 47: 9-17.
71. Jean WC, Dalmau J, Ho A, Posner JB. Analysis of the IgG subclass distribution and inflammatory infiltrates in patients with anti-Hu-associated paraneoplastic encephalomyelitis. Neurology 1994; 44: 140-147.
72. Shams'ili S, Grefkens J, de Leeuw B, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain 2003; 126: 1409-1418.
73. Bernal F, Shams'ili S, Rojas I, et al. Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. Neurology 2003; 60: 230-234.
74. Klockgether T. Sporadic ataxia with adult onset: classification and diagnostic criteria. Lancet Neurol 2010; 9: 94-104.
75. Burk K, Wick M, Roth G, Decker P, Voltz R. Antineuronal antibodies in sporadic late-onset cerebellar ataxia. J Neurol 2010; 257: 59-62.
76. Matsumoto L, Yamamoto T, Higashihara M, et al. Severe hypokinesis caused by paraneoplastic anti-Ma2 encephalitis associated with bilateral intratubular germ-cell neoplasm of the testes. Mov Disord 2007; 22: 728-731.
77. Dalmau J Graus F, Villarejo A, et al. Clinical analysis of anti-Ma2-associate encephalitis. Brain 2004; 127: 1831-1844.
78. Johannis W, la Fougere C, Newman T, Vincent A, Voltz R. Anti-Ma and anti-Ta associated paraneoplastic neurological syndromes: 22 newly diagnosed patients and review of previous cases. J Neurol Neurosurg Psychiatry 2008; 79: 767-773.
79. Vermino S, Tuite P, Adler CH, et al. Paraneoplastic chorea associated with CRMP-5 neuronal antibody and lung carcinoma. Ann Neurol 2002; 51: 625-630.
80. Samii A, Dahlen DD, Spence AM, Maronian NC, Kraus EE, Lennon VA. Paraneoplastic movement disorder in a patient with non-Hodgkin's lymphoma and CRMP-5 autoantibody. Mov Disord 2003; 18: 1556-1558.
81. Casado JL, Gil-Peralta A, Graus F, Arenas C, Lopez JM, Alberca R. Anti-Ri antibodies associated with opsoclonus and progressive encephalomyelitis with rigidity. Neurology 1994; 44: 1521-1522.
82. Kirsten A, Beck S, Fühlhuber V, et al. New autoantibodies in pediatric opsoclonus myoclonus syndrome. Ann NY Acad Sci 2007; 1110: 256-260.
83. Jankovic J. Progressive supranuclear palsy: Paraneoplastic effect of bronchial carcinoma. Neurology 1985; 35: 446-447.
84. Golbe LI, Miller DC, Duvoisin RC: Paraneoplastic degeneration of the substantia nigra with dystonia and parkinsonism. Mov Disord 1989; 4: 147-152.
85. Graus F, Saiz A, Lai M, et al. Neuronal surface antigen antibodies in limbic encephalitis: clinical-immunologic associations. Neurology 2008; 71: 930-936.
86. Darnell RB, Posner JB. Autoimmune encephalopathy: the spectrum widens. Ann Neurol. 2009; 66: 1-2.
87. Lai M, Hughes EG, Pehng X, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol. 2009; 65: 424-434.
88. Lancaster E, Lai M, Peng X, et al. The GABA-B receptor is a novel autoantigen of limbic encephalitis with prominent seizures: a case series and characterization of the antigen. Lancet Neurol 2010; 9: 67-76.
89. Tan KM, Lennon VA, Klein CJ, Boeve BF, Pittock SJ. Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology 2008; 70: 1883-1890.
90. Geschwind MD, Tan KM, Lennon VA, et al. Voltage-gated potassium channel autoimmunity mimicking Creutzfeldt-Jakob disease. Arch Neurol 2008; 65: 1341-1346.
91. Lai M, Huijbers MG, Lancaster E, et al. Investigations of LGI as the antigen of limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 2010; 9: 776-785.
92. Kaymakamzade B, Kansu T, Tan E, Dericioǧlu N. LGI1 related limbic encephalitis and response to immunosuppressive therapy. J Neurol 2011; 258: 2075-2077.
93. Andrade DM, Tai P, Dalmau J, Wennberg R. Tonic seizures: a diagnostic clue of anti-LGI1 encephalitis? Neurology 2011; 76: 1355-1357.
94. Irani SR, Michell AW, Lang B, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 2011; 69: 892-900.
95. Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010; 133: 2734-2748.
96. Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology 2011; 77: 179-189.
97. Dalmau J, Tuzun E, Wu HY, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007; 61: 25-36.
98. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008; 7: 1091-1098.
99. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011; 10: 63-74.
100. Irani SR, Bera K, Waters P, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010; 133: 1655-1667.
101. Florance NR, Davis RL, Lam C, et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol 2009; 66: 11-18.
102. Kurian M, Lalive PH, Dalmau JO, Horvath J. Opsoclonus-myoclonus syndrome in anti-N-methyl-D-aspartate receptor encephalitis. Arch Neurol 2010; 67: 118-121.
103. Gabilondo I, Saiz A, Galán L, et al. Analysis of relapses in anti-NMDAR encephalitis. Neurology 2011; 77: 996-999.
104. Saiz A, Blanco Y, Sabater L, et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain 2008; 131: 2553-2563.
105. McHugh JC, Murray B, Renganathan R, Connolly S, Lynch T. GAD antibody positive paraneoplastic stiff person syndrome in a patient with renal cell carcinoma. Mov Disord 2007; 22: 1343-1346.
106. Honnorat J, Saiz A, Giometto B, et al. Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies. Arch Neurol 2001; 58: 225-230.
107. Mata' S, Muscas GC, Naldi I, et al. Nonparaneoplastic limbic encephalitis associated with anti-glutamic acid decarboxylase antibodies. J Neuroimmunol 2008; 199: 155-159.
108. Blum P, Jankovic J. Stiff-person syndrome: an autoimmune disease. Mov Disord 1991; 6: 12-20.
109. Witherick J, Highley JR, Hadjivassiliou M. Pathological findings in a case of stiff-person syndrome with anti-GAD antibodies. Mov Disord 2011; 26: 2138-2139.
110. Murinson BB, Guarnaccia JB. Stiff-person syndrome with amphiphysin antibodies: distinctive features of a rare disease. Neurology 2008; 71: 1955-1958.
111. McKeon A, Robinson MT, McEvoy KM, et al. Stiff-man syndrome and variants: clinical course, treatment, and outcomes. Arch Neurol 2012; 69: 230-238.
112. Hutchinson M, Waters P, McHugh J, et al. Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody. Neurology 2008; 71: 1291-1292.
113. Mas N, Saiz A, Leite MI, et al. Antiglycine-receptor encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry 2011; 82: 1399-1401.
114. Castillo P, Woodruff B, Caselli R, et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis. Arch Neurol 2006; 63: 197-202.
115. Bien CG, Granata T, Antozzi C, et al. Pathogenesis, diagnosis and treatment of Rasmussen encephalitis. A European consensus statement. Brain 2005; 128: 454-471.
116. Alvarez-Barón E, Bien CG, Schramm J, Elger CE, Becker AJ, Schoch S. Autoantibodies to Munc 18, cerebral plasma cells and B-lymphocytes in Rasmussen encephalitis. Epilepsy Res 2008; 80: 93-97.
117. Andermann F. Rasmussen syndrome and movement disorder. Mov Disord 2002; 17: 437-438.
118. Shams'ili S, de Beukelaar J, Gratama JW, et al. An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol 2006; 253: 16-20.
119. Qureshi A, Hennessy M. Stiff person syndrome (SPS) complicated by respiratory failure: successful treatment with rituximab. J Neurol 2012; 259: 180-181.
120. Bataller L, Kleopa KA, Wu GF, et al. Autoimmune limbic encephalitis in 39 patients: immunophenotypes and outcomes. J Neurol Neurosurg Psychiatry 2007; 78: 381-385.
121. Duddy ME, Baker MR. Stiff person syndrome. Front Neurol Neurosci 2009; 26: 147-165.
122. Browner N, Azher SN, Jankovic J. Botulinum toxin treatment of facial myoclonus in suspected Rasmussen encephalitis. Mov Disord 2006; 21: 1500-1502.
123. Frucht S. Dystonia, athetosis, and epilepsia partialis continua in a patient with late-onset Rasmussen's encephalitis. Mov Disord 2002; 17: 609-612.
124. Graus F, Keime-Guibert F, Reñe R, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001; 124: 1138-1148.
125. Panzer J, Dalmau J. Movement disorders in paraneoplastic and autoimmune disease. Curr Opin Neurol 2011; 24: 346-353.
126. Lancaster E, Martinez-Hernandez E, Titulaer MJ, et al. Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome. Neurology 2011; 77: 1698-1701.
127. Zuliani L, Sabater L, Saiz A, Baiges JJ, Giometto B, Graus F. Homer 3 autoimmunity in subacute idiopathic cerebellar ataxia. Neurology 2007; 68: 239-240.
128. Tsokos GC. Systemic lupus erythematosus. N Engl J Med 2011; 365: 2110-2121.
129. Cervera R, Asherson RA, Font J, et al. Chorea in the antiphospholipid syndrome: clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature. Medicine (Baltimore) 1997; 76: 203-212.
130. Baizabal Carvallo JF, Alonso-Juarez M, Koslowski M. Chorea in SLE. J Clin Rheumatol 2011; 17: 69-72.
131. Asherson RA, Derksen RH, Harris EN, et al. Chorea in systemic lupus erythematosus and "lupus-like" disease: association with antiphospholipid antibodies. Semin Arthritis Rheum 1987; 16: 253-259.
132. Rafai MA, El Moutawakil B, Gam I, et al. Systemic lupus erythematosus presenting with a choreo-athetosic syndrome associated with antiphospholipid antibodies. Rev Neurol (Paris) 2005; 161: 967-970.
133. Orzechowski NM, Wolanskyj AP, Ahlskog JE, Kumar N, Moder KG. Antiphospholipid antibody-associated chorea. J Rheumatol 2008; 35: 2165-2170.
134. Thomas D, Byrne PD, Travers RL. Systemic lupus erythematosus presenting as post-partum chorea. Aust NZ J Med 1979; 9: 568-570.
135. Khamashta MA, Gil A, Anciones B, et al. Chorea in systemic lupus erythematosus: association with antiphospholipid antibodies. Ann Rheum Dis 1988; 47: 681-683.
136. Zandman-Goddard G, Chapman J, Shoenfield Y. Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. Semin Arthritis Rheum 2007; 36: 297-315.
137. Galanaud D, Dormont D, Marsault C, Wechsler B, Piette JC. Brain MRI in patients with past lupus-associated chorea. Stroke 2000; 31: 3079-3083.
138. Al Jishi F, Al Kawi MZ, El Ramahi K, Omer S. Hemichorea in systemic lupus erythematosus: significance of MRI findings. Lupus 1995; 4: 321-323.
139. Kuroe K, Kurahashi K, Nakano I, Morimatsu Y, Takemori H. A neuropathological study of a case of lupus erytematosus with chorea. J Neurol Sci 1994; 123: 59-63.
140. Reiner P, Galanaud D, Leroux G, et al. Long-term outcome of 32 patients with chorea and systemic lupus erythematosus and antiphospholipid syndrome. Mov Disord 2011; 26: 2422-2427.
141. Krakauer M, Law I. FDG PET brain imaging in neuropsychiatric systemic lupus erythematosus with choreic symptoms. Clin Nucl Med 2009; 34: 122-123.
142. Sundén-Cullberg JL, Tedroff J, Aquilonius SM. Reversible chorea in primary antiphospholipid syndrome. Mov Disord 1998; 13: 147-149.
143. Wu SW, Graham B, Gelfand MJ, Gruppo RE, Dinopolous A, Gilbert DL. Clinical and positron emission tomography findings of chorea associated with primary antiphospholipid antibody syndrome. Mov Disord 2007; 22: 1813-1815.
144. Furie R, Ishikawa T, Dhawan V, Eidelberg D. Alternating hemichorea in primary antiphospholipid syndrome: evidence for contralateral striatal hypermetabolism. Neurology 1994; 44: 2197-2199.
145. Song CH, Oftadeh LC, Oh C, Louie J, Yu KT. Successful treatment of steroid-resistant chorea associated with lupus by use of valproic acid and clonidine-HCL patch. Clin Pediatr (Phila) 1997; 36: 659-662.
146. Nordal EB, Nielsen J, Marhaug G: Chorea in juvenile primary antiphospholipid syndrome-reversible decreased circulation in the basal ganglia visualized by single photon emission computed tomography. Scand J Rheumatol 1999; 28: 324-327.
147. Lazurova I, Macejova Z, Benhatchi K, Oetterova M, Antolova E, Asherson RA, Rovensky J. Efficacy of intravenous immunoglobulin treatment in lupus erythematosus chorea. Clin Rheumatol 2007; 26: 2145-2147.
148. Tan EK, Chan TT, Auchus AP. Reversible parkinsonism in systemic lupus erythematosus. J Neurol Sci 2001; 193: 53-57.
149. Joseph FG, Lammie GA, Scolding NJ. CNS lupus: a study of 41 patients. Neurology 2007; 69: 644-654.
150. San-Juan Orta D, Rodríguez Ortiz U. Stroke of the substance nigra and parkinsonism as first manifestation of systemic lupus erythematosus. Parkinsonism Relat Disord 2008; 14: 367-369.
151. Kunas RC, McRae A, Kesselring J, Villiger PM. Antidopaminergic antibodies in a patient with a complex autoimmune disorder and rapidly progressing Parkinson's disease. J Allergy Clin Immunol 1995; 96: 688-690.
152. Garcia-Moreno JM, Chacon J. Juvenile parkinsonism as a manifestation of systemic lupus erythematosus: case report and review of the literature. Mov Disord 2002; 17: 1329-1335.
153. Kwong KL, Chu R, Wong SN. Parkinsonism as unusual neurological complication in childhood systemic lupus erythematosus. Lupus 2000; 9: 474-477.
154. Khubchandani RP, Viswanathan V, Desai J. Unusual neurologic manifestations (I): parkinsonism in juvenile SLE. Lupus 2007; 16: 572-575.
155. Fabiani G, Teive HA, Germiniani FM, Sá DS, Werneck LC. Reversible parkinsonian syndrome in systemic and brain vasculitis. Mov Disord 2002; 17: 601-604.
156. Lim SM, Oldfield M, Abbott RJ. Systemic lupus erythematosus presenting with steroid-responsive parkinsonism and post-hemiplegic dystonia. Eur J Neurol 1998; 5: 309-312.
157. Shahar E, Goshen E, Tauber Z, Lahat E. Parkinsoniam syndrome complicating systemic lupus erythematosus. Pediatr Neurol 1998; 18: 456-458.
158. Appenzeller S, Cendes F, Costallat LT. Cerebellar ataxia in systemic lupus erythematosus. Lupus 2008; 17: 1122-1126.
159. Yaginuma M, Suenaga M, Shiono Y, Sakamoto M. Acute cerebellar ataxia of a patient with SLE. Clin Neurol Neurosurg 2000; 102: 37-39.
160. Manto MU, Rondeaux P, Jacquy J, Hildebrand JG: Subacute pancerebellar syndrome associated with systemic lupus erythematosus. Clin Neurol Neurosurg 1996; 98: 157-160.
161. Singh RR, Prasad K, Kumar A, Misra A, Padmakumar K, Malaviya AN. Cerebellar ataxia in systemic lupus erythematosus: three case reports. Ann Rheum Dis 1988; 47: 954-956.
162. Kwon SU, Koh JY, Kim JS. Vertebrobasilar artery territory infarction as an initial manifestation of systemic lupus erythematosus. Clin Neurol Neurosurg 1999; 101: 62-67.
163. Robert M, Sunitha R, Thulaseedharan NK. Neuropsychiatric manifestations systemic lupus erythematosus: a study from South India. Neurol India 2006; 54: 75-77.
164. Jankovic J, Patten BM. Blepharospasm and autoimmune diseases. Mov Disord 1987; 2: 159-163.
165. Rajagopalan N, Humphrey PR, Bucknall RC. Torticollis and blepharospasm in systemic lupus erythematosus. Mov Disord 1989; 4: 345-348.
166. Munhoz RP, Fameli H, Teive HAG. Stiff person syndrome as the initial manifestation of systemic lupus erythematosus. Mov Disord 2010; 25: 516-517.
167. Goëb V, Dubreuil F, Cabre P, Jean Baptiste G, Arfi S. Lupus revealing itself after a stiff-person syndrome. Lupus 2004; 13: 215.
168. Engelen M, Tijssen MA. Paroxysmal non-kinesigenic dyskinesia in antiphospholipid syndrome. Mov Disord 2005; 20: 111-113.
169. Angelini L, Zibordi F, Zorzi G, et al. Neurological disorders, other than stroke, associated with antiphospholipid antibodies in childhood. Neuropediatrics 1996; 27: 149-153.
170. Milanov I, Bogdanova D. Antiphospholipid syndrome and dystonia-parkinsonism: a case report. Parkinsonism Relat Disord 2001; 7: 139-141.
171. Morris HR, Lees AJ. Primary antiphospholipid syndrome presenting as a corticobasal degeneration syndrome. Mov Disord 1999; 14: 530-531.
172. Martino D, Chew NK, Mir P, Edwards MJ, Quinn NP, Bhatia KP. Atypical movement disorders in antiphospholipid syndrome. Mov Disord 2006; 21: 944-949.
173. Bardella D, Rossi ML, Temporin G. Infantile cerebellar thrombosis: a case of lupus anticoagulants? Pediatr Med Chir 2002; 24: 392-393.
174. Toren P, Toren A, Weizman A, et al. Tourette's disorder: is there an association with the antiphospholipid syndrome? Biol Psychiatry 1994; 35: 495-498.
175. Singer HS, Krumholz A, Giuliano J, Kiessling LS. Antiphospholipid antibodies: An epiphenomenon in Tourette syndrome. Mov Disord 1997; 12: 738-742.
176. Hadjivassiliou M, Sanders DS, Grünewald RA, Woodroofe N, Boscolo S, Aeschlimann D. Gluten sensitivity: from gut to brain. Lancet Neurol 2010; 9: 318-330.
177. Bürk K, Farecki ML, Lamprecht G, et al. Neurological symptoms in patients with biopsy proven celiac disease. Mov Disord 2009; 24: 2358-2362.
178. Zelnik N, Pacht A, Obeid R, Lerner A. Range of neurologic disorders in patients with celiac disease. Pediatrics 2004; 113: 1672-1676.
179. Hadjivassiliou M, Boscolo S, Tongiorgi E, et al. Cerebellar ataxia as a possible organ-specific autoimmune disease. Mov Disord 2008; 23: 1370-1377.
180. Burk K, Melms A, Schulz JB, Dichgans J. Effectiveness of intravenous immunoglobulin therapy in cerebellar ataxia associated with gluten sensitivity. Ann Neurol 2001; 50: 827-828.
181. Hadjivassiliou M, Davies-Jones GAB, Sanders DS, Grünewald RAG. Dietary treatment of gluten ataxia. J Neurol Neurosurg Psychiatry 2003; 74: 1221-1224.
182. Hadjivassiliou M, Grünewald R, Sharrack B, et al. Gluten ataxia in perspective: epidemiology, genetic susceptibility and clinical characteristics. Brain 2003; 126: 685-691.
183. Hadjivassiliou M, Rao DG, Wharton SB, Sanders DS, Grünewald RA, Davies-Jones AG. Sensory ganglionopathy due to gluten sensitivity. Neurology 2010; 75: 1003-1008.
184. Ihara M, Makino F, Sawada H, et al. Gluten sensitivity in Japanese patients with adult-onset cerebellar ataxia. Intern Med 2006; 45: 135-140.
185. Anheim M, Degos B, Echaniz-Laguna A, Fleury M, Grucker M, Tranchant C. Ataxia associated with gluten sensitivity, myth or reality? Rev Neurol (Paris) 2006; 162: 214-221.
186. Bhatia KP, Brown P, Gregory R, et al. Progressive myoclonic ataxia associated with coeliac disease. The myoclonus is of cortical origin, but the pathology is in the cerebellum. Brain 1995; 118: 1087-1093.
187. Finelli PF, McEntee WJ, Ambler M, Kestenbaum D. Adult celiac disease presenting as cerebellar syndrome. Neurology 1980; 30: 245-249.
188. Hadjivassiliou M, Grunewald RA, Chattopadhyay AK, et al. Clinical, radiological, neurophysiological and neuropathological characteristics of gluten ataxia. Lancet 1998; 352: 1582-1585.
189. Abele M, Bürk K, Schöls L, et al. The aetiology of sporadic adult-onset ataxia. Brain. 2002; 125: 961-968.
190. Pellecchia MT, Ambrosio G, Salvatore E, Vitale C, De Michele G, Barone P. Possible gluten sensitivity in multiple system atrophy. Neurology 2002; 59: 1114-1115.
191. Almaguer-Mederos LE, Almira YR, Gongora EM, et al. Antigliadin antibodies in Cuban patients with spinocerebellar ataxia type 2. J Neurol Neurosurg Psychiatry 2008; 79: 315-317.
192. Hall DA, Parsons J, Benke T. Paroxysmal nonkinesigenic dystonia and celiac disease. Mov Disord 2007; 22: 708-710.
193. Pereira AC, Edwards MJ, Buttery PC, et al. Choreic syndrome and coeliac disease: a hitherto unrecognised association. Mov Disord 2004; 19: 478-482.
194. Gonzalez Aleman G, Florenzano N, Padilla E, et al. A 37-year-old woman with celiac disease, recurrent psychosis, and parkinsonism. Mov Disord 2006; 21: 729-731.
195. Hadjivassiliou M, Aeschlimann D, Grünewald RA, Sanders DS, Sharrack B, Woodroofe N. GAD antibody-associated neurological illness and its relationship to gluten sensitivity. Acta Neurol Scand. 2011; 123: 175-180.
196. Mahad D, Oates K, Williams C, et al. Gluten ataxia is immune mediated. J Neurol Neurosurg Psychiatry 2002; 72: 140.
197. Boscolo S, Sarich A, Lorenzon A, et al. Gluten ataxia: passive transfer in a mouse model. Ann N Y Acad Sci 2007; 1107: 319-328.
198. Hadjivassiliou M, Mäki M, Sanders DS, et al. Autoantibody targeting of brain and intestinal transglutaminase in gluten ataxia. Neurology 2006; 66: 373-377.
199. Freeman HJ. Neurological disorders in adult celiac disease. Can J Gastroenterol 2008; 22: 909-911.
200. Souayah N, Chin RL, Brannagan TH, et al. Effect of intravenous immunoglobulin on cerebellar ataxia and neuropathic pain associated with celiac disease. Eur J Neurol 2008; 15: 1300-1303.
201. Delalande S, de Seze J, Fauchais AL, et al. Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine (Baltimore) 2004; 83: 280-291.
202. Rosenbaum R, Barkhuizen A. Primary Sjögren's syndrome. In: Noseworthy JH, ed. Neurological Therapeutics: Principles and Practice. 2nd ed. London, UK: Informa Healthcare 2006: 1587-1591.
203. Créange A, Sedel F, Brugières P, Voisin MC, Degos JD. Primary Sjögren's syndrome presenting as progressive parkinsonian syndrome. Mov Disord. 1997; 12: 121-123.
204. Visser LH, Koudstaal PJ, van de Merwe JP. Hemiparkinsonism in a patient with primary Sjögren's syndrome. A case report and a review of the literature. Clin Neurol Neurosurg 1993; 95: 141-145.
205. Walker RH, Spiera H, Brin MF, Olanow CW. Parkinsonism associated with Sjögren's syndrome: three cases and review of the literature. Mov Disord 1999; 14: 262-268.
206. Hassin-Baer S, Levy Y, Langevitz P, Nakar S, Ehrenfeld M. Anti-beta2-glycoprotein I in Sjögren syndrome is associated with parkinsonism. Clin Rheumatol 2007; 26: 743-747.
207. Nishimura H, Tachibana H, Makiura N, Okuda B, Sugita M. Corticosteroid-responsive parkinsonism associated with primary Sjögren's syndrome. Clin Neurol Neurosurg 1994; 96: 327-331.
208. Min JH, Youn YC. Bilateral basal ganglia lesions of primary Sjögren syndrome presenting with generalized chorea. Parkinsonism Relat Disord 2009; 15: 398-399.
209. Venegas Fanchke P, Sinning M, Miranda M. Primary Sjögren's syndrome presenting as a generalized chorea. Parkinsonism Relat Disord 2005; 11: 193-194.
210. van den Berg JS, Horstink MW, van den Hoogen FH, Oyen WJ. Dystonia; a central nervous system presentation of Sjögren's syndrome. Mov Disord 1999; 14: 374-375.
211. Alonso-Navarro H, Arroyo M, Parra A, Jimenez-Jimenez FJ. Paroxysmal dystonia associated to primary Sjögren's syndrome. Mov Disord 2009; 24: 788-790.
212. Papageorgiou SG, Kontaxis T, Bonakis A, Kalfakis N. Orofacial dystonia related to Sjögren's syndrome. Clin Rheumatol 2007; 26: 1779-1781.
213. *0604) homozygotes are at greatly increased risk of cervical dystonia in Caucasian Americans. Autoimmunity 2011; 44: 167-176.